Scorpius Holdings, Inc.

NYSEAM:SCPX 株式レポート

時価総額:US$2.2m

Scorpius Holdings 過去の業績

過去 基準チェック /06

Scorpius Holdings's earnings have been declining at an average annual rate of -15.9%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 13.5% per year.

主要情報

-15.9%

収益成長率

26.9%

EPS成長率

Biotechs 業界の成長17.0%
収益成長率13.5%
株主資本利益率-144.8%
ネット・マージン-300.4%
前回の決算情報30 Jun 2024

最近の業績更新

Recent updates

Here's Why We're Watching Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation

Dec 28
Here's Why We're Watching Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation

Here's Why We're Not Too Worried About Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation

Sep 02
Here's Why We're Not Too Worried About Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation

Heat Biologics names Anthony Manning as chief scientific advisor

May 10

Heat Biologics EPS misses by $0.01, misses on revenue

May 05

We're Hopeful That Heat Biologics (NASDAQ:HTBX) Will Use Its Cash Wisely

Apr 30
We're Hopeful That Heat Biologics (NASDAQ:HTBX) Will Use Its Cash Wisely

Reflecting on Heat Biologics' (NASDAQ:HTBX) Share Price Returns Over The Last Five Years

Mar 07
Reflecting on Heat Biologics' (NASDAQ:HTBX) Share Price Returns Over The Last Five Years

Here's Why We're Not Too Worried About Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation

Jan 13
Here's Why We're Not Too Worried About Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation

収支内訳

Scorpius Holdings の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

NYSEAM:SCPX 収益、費用、利益 ( )USD Millions
日付収益収益G+A経費研究開発費
30 Jun 2410-30230
31 Mar 2410-32250
31 Dec 237-40260
30 Sep 232-51260
30 Jun 232-50250
31 Mar 231-45230
31 Dec 220-41200
30 Sep 221-38190
30 Jun 221-36180
31 Mar 222-36160
31 Dec 212-35170
30 Sep 212-28140
30 Jun 212-29170
31 Mar 213-27160
31 Dec 203-26150
30 Sep 204-23140
30 Jun 204-2090
31 Mar 203-2190
31 Dec 193-2090
30 Sep 193-2290
30 Jun 195-1990
31 Mar 196-1890
31 Dec 186-1670
30 Sep 184-1460
30 Jun 183-1360
31 Mar 182-1260
31 Dec 172-1260
30 Sep 171-1260
30 Jun 171-1150
31 Mar 170-1150
31 Dec 160-1340
30 Sep 160-164-2
30 Jun 160-195-1
31 Mar 160-214-1
31 Dec 150-2050
30 Sep 150-1742
30 Jun 150-1543
31 Mar 150-1343
31 Dec 140-1243
30 Sep 140-1043
30 Jun 140-1043
31 Mar 140-833

質の高い収益: SCPX is currently unprofitable.

利益率の向上: SCPX is currently unprofitable.


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: SCPX is unprofitable, and losses have increased over the past 5 years at a rate of 15.9% per year.

成長の加速: Unable to compare SCPX's earnings growth over the past year to its 5-year average as it is currently unprofitable

収益対業界: SCPX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


株主資本利益率

高いROE: SCPX has a negative Return on Equity (-144.8%), as it is currently unprofitable.


総資産利益率


使用総資本利益率


過去の好業績企業の発掘